Both Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Mustang Bio Inc. (NASDAQ:MBIO) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Crinetics Pharmaceuticals Inc.||2.43M||257.94||27.11M||-0.91||0.00|
|Mustang Bio Inc.||N/A||0.00||30.66M||-1.30||0.00|
Table 1 showcases the gross revenue, earnings per share and valuation of Crinetics Pharmaceuticals Inc. and Mustang Bio Inc.
Table 2 provides us the return on equity, net margins and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Crinetics Pharmaceuticals Inc.||-1,115.64%||0%||0%|
|Mustang Bio Inc.||0.00%||-65.1%||-60%|
The Current Ratio and Quick Ratio of Crinetics Pharmaceuticals Inc. are 31 and 31 respectively. Its competitor Mustang Bio Inc.’s Current Ratio is 10.3 and its Quick Ratio is 10.3. Crinetics Pharmaceuticals Inc. can pay off short and long-term obligations better than Mustang Bio Inc.
Crinetics Pharmaceuticals Inc. and Mustang Bio Inc. Recommendations and Ratings are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Crinetics Pharmaceuticals Inc.||0||0||1||3.00|
|Mustang Bio Inc.||0||0||0||0.00|
Crinetics Pharmaceuticals Inc.’s upside potential currently stands at 54.74% and an $40 average target price.
Insider & Institutional Ownership
Crinetics Pharmaceuticals Inc. and Mustang Bio Inc. has shares owned by institutional investors as follows: 98.6% and 9.6%. Insiders owned roughly 5.66% of Crinetics Pharmaceuticals Inc.’s shares. Competitively, 1.1% are Mustang Bio Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Crinetics Pharmaceuticals Inc.||2.61%||-8.83%||-31.68%||-22.38%||0%||-20.11%|
|Mustang Bio Inc.||-13.73%||1.34%||-2.08%||-45.36%||-64.63%||28.23%|
For the past year Crinetics Pharmaceuticals Inc. had bearish trend while Mustang Bio Inc. had bullish trend.
Crinetics Pharmaceuticals Inc. beats Mustang Bio Inc. on 8 of the 10 factors.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.